| 000 | 01627 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515025549.0 | ||
| 264 | 0 | _c20061114 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a0017-5749 | ||
| 024 | 7 |
_a10.1136/gut.2005.083113 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSherman, M | |
| 245 | 0 | 0 |
_aPeginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. _h[electronic resource] |
| 260 |
_bGut _cNov 2006 |
||
| 300 |
_a1631-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Dropouts |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadverse effects |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aRibavirin _xadverse effects |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aYoshida, E M | |
| 700 | 1 | _aDeschenes, M | |
| 700 | 1 | _aKrajden, M | |
| 700 | 1 | _aBain, V G | |
| 700 | 1 | _aPeltekian, K | |
| 700 | 1 | _aAnderson, F | |
| 700 | 1 | _aKaita, K | |
| 700 | 1 | _aSimonyi, S | |
| 700 | 1 | _aBalshaw, R | |
| 700 | 1 | _aLee, S S | |
| 773 | 0 |
_tGut _gvol. 55 _gno. 11 _gp. 1631-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/gut.2005.083113 _zAvailable from publisher's website |
| 999 |
_c16308905 _d16308905 |
||